Prothena Corp PLC (PRTA)
47.07
-1.00 (-2.08%)
USD |
NASDAQ |
Mar 24, 16:00
48.01
+0.94 (+2.00%)
After-Hours: 20:00
Prothena Revenue (TTM): 53.90M for Dec. 31, 2022
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2022 | 53.90M |
September 30, 2022 | 5.154M |
June 30, 2022 | 142.81M |
March 31, 2022 | 201.57M |
December 31, 2021 | 200.58M |
September 30, 2021 | 199.76M |
June 30, 2021 | 60.75M |
March 31, 2021 | 0.872M |
December 31, 2020 | 0.853M |
September 30, 2020 | 0.749M |
June 30, 2020 | 0.797M |
March 31, 2020 | 0.769M |
December 31, 2019 | 0.814M |
September 30, 2019 | 0.752M |
June 30, 2019 | 0.802M |
March 31, 2019 | 0.914M |
December 31, 2018 | 0.955M |
September 30, 2018 | 0.99M |
June 30, 2018 | 0.954M |
March 31, 2018 | 27.49M |
December 31, 2017 | 27.52M |
Date | Value |
---|---|
September 30, 2017 | 27.46M |
June 30, 2017 | 27.53M |
March 31, 2017 | 1.049M |
December 31, 2016 | 1.055M |
September 30, 2016 | 1.191M |
June 30, 2016 | 1.334M |
March 31, 2016 | 1.279M |
December 31, 2015 | 1.607M |
September 30, 2015 | 3.313M |
June 30, 2015 | 4.37M |
March 31, 2015 | 19.21M |
December 31, 2014 | 50.85M |
September 30, 2014 | 49.01M |
June 30, 2014 | 47.69M |
March 31, 2014 | 32.74M |
December 31, 2013 | 0.676M |
September 30, 2013 | 1.084M |
June 30, 2013 | 1.857M |
March 31, 2013 | 2.425M |
December 31, 2012 | 2.658M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.749M
Minimum
Sep 2020
201.57M
Maximum
Mar 2022
45.11M
Average
0.9545M
Median
Revenue (TTM) Benchmarks
Mallinckrodt PLC | 1.914B |
Jazz Pharmaceuticals PLC | 3.659B |
Nabriva Therapeutics PLC | 34.14M |
Iterum Therapeutics PLC | -- |
GH Research PLC | -- |